Ligand Pharmaceuticals Incorporated
LGND Healthcare Biotechnology
Ligand Pharmaceuticals Incorporated’s revenue for fiscal 2025 (year ended December 2025) was $268.1 million, up 60.4% from fiscal 2024. In the quarter to June 2026, revenue grew 33.7%, EPS grew 868.0% and free cash flow grew 35.5%, each against the same quarter a year earlier.
Follow LGND
Ligand Pharmaceuticals Incorporated (LGND) EV/Sales
As of 16 October 2026, Ligand Pharmaceuticals Incorporated (LGND) trades at a EV/Sales of 19.8×. Over the past ten years it has ranged from 1.8× (September 2019) to 22.7× (April 2016); the current reading is higher than 96% of that period. That is above the Biotechnology industry median of 9.2× and above the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 12.8× | 20.13% |
| FY2024 | 10.6× | 19.98% |
| FY2023 | 8.9× | 75.85% |
| FY2022 | 5.0× | (23.18%) |
| FY2021 | 6.6× | 2.82% |
| FY2020 | 6.4× | (4.80%) |
| FY2019 | 6.7× | 1.88% |
| FY2018 | 6.6× | (50.13%) |
| FY2017 | 13.2× | 0.25% |
| FY2016 | 13.2× | (31.46%) |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 21.3× | 57.57% |
| Mar 2026 | 13.5× | 5.63% |
| Dec 2025 | 12.8× | (3.19%) |
| Sep 2025 | 13.2× | 21.58% |
| 42 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| BLTE Belite Bio, Inc. Sponsored ADR compare | n/m |
| ERAS Erasca, Inc. compare | n/m |
| IMVT Immunovant, Inc. compare | n/m |
| KOD Kodiak Sciences Inc. compare | n/m |
| MIRM Mirum Pharmaceuticals, Inc. compare | 8.7× |
| IOVA Iovance Biotherapeutics, Inc. compare | 17.9× |
| LGND Ligand Pharmaceuticals Incorporated | 19.8× |
| RYTM Rhythm Pharmaceuticals, Inc. compare | 23.3× |
| CGON CG Oncology, Inc. compare | 684× |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)